Jim Cramer - Mad Money Mind Medicine (MindMed) MNMD-Q PARTIAL BUY Apr 10, 2024

Last month, they received therapy designation to use their LSD program that treats anxiety. Shares have since jumped 80%.

Jim Cramer - Mad Money

Unlock Rating

$10.880

Stock price when the opinion was issued

biotechnology

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

RISKY

He thought psychedelic drugs had a future, but it's in the past. A great spec, but warnings: stocks can go to zero.

Most Recent Experts

Jeff Parent B. Eng. FCSI CIM

Castlemoore Inc.

Stockchase Insights

5i Research

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Mind Medicine (MindMed) MNMD-Q PARTIAL BUY Apr 10, 2024

You might be interested:

Mind Medicine (MindMed)(MNMD-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals